TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22692637
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) 850 mg twice daily
Study: 20110592
Drug: Complex antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex antioxidant blend (active treatment) for four months
Study: 20110592
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (identical gel and bottle) for four months
Study: 20110592
Drug: Complex antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex antioxidant blend (active treatment)
Study: 16136166
Drug: Chemotherapy (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (without donor)
Study: 11903940
Drug: Single Shot
Normalized name: ACL7 SINGLE SHOT EPIDURAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Shot (SS) technique with 0.25 ml x kg(‐1) of 0.25% bupivacaine
Study: 11903940
Drug: Double Shot
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Shot (DS) technique with one-third of total dose of bupivacaine given as SS and remaining two-thirds deposited above and lateral to mid‐inguinal point
Study: 9508163
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus chemotherapy
Study: 2116082
Drug: CA 300
Normalized name: Lyrica 300mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 300 mg alone
Study: 2116082
Drug: CA 200
Normalized name: DCA 2000 Normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 200 mg + mitomycin C (MMC) 10 mg
Study: 2116082
Drug: CA 180
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 180 mg + adriamycin (ADM) 20 mg
Study: 387225
Drug: cis‐dichlorodiammineplatinum(II) (cis‐platinum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis‐dichlorodiammineplatinum(II) (cis‐platinum) at doses of 30 mg/m2
Study: 387225
Drug: cis‐dichlorodiammineplatinum(II) (cis‐platinum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis‐dichlorodiammineplatinum(II) (cis‐platinum) at doses of 100 mg/m2
Study: 387225
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chlorambucil and cis‐platinum (regimen B)
Study: 387225
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chlorambucil, cis‐platinum, and Adriamycin (regimen C)
Study: 16096124
Drug: Non-preferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-preferred treatment
Study: 17107904
Drug: Chlorambucil 20
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil 20 mg m‐2 for 3 days and dexamethasone 4 mg bd for 5 days plus oral idarubicin 10 mg m‐2 for 3 days (CID)
Study: 17107904
Drug: Chlorambucil 20
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil 20 mg m‐2 for 3 days and dexamethasone 4 mg bd for 5 days (CD)
Study: 11768840
Drug: Cefprozil (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil (15 mg/kg per day in 2 divided doses for 10 days)
Study: 11768840
Drug: Erythromycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (30 mg/kg per day in 3 divided doses for 10 days)
Study: 3307308
Drug: Metoprolol (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (3.0 mg i.v. bolus followed by an i.v. infusion of 4.8 mg/h)
Study: 3307308
Drug: Insulin (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (2.4 U/h i.v. infusion over 180 min)
Study: 31702602
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) and telephone counseling
Study: 23683751
Drug: MAL-PDT (methylaminolevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL-PDT (methylaminolevulinate photodynamic therapy; two sessions with an interval of 1 week)
Study: 23683751
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream (once daily, five times a week for 6 weeks)
Study: 23683751
Drug: Fluorouracil cream
Normalized name: Fluorouracil Cream
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil cream (twice daily for 4 weeks)
Study: 16083385
Drug: Korean MMPI-2
Normalized name: Korean ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean MMPI-2 L, K, and S scales
Study: 7675553
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (CONT)
Study: 1974429
Drug: Flutoprazepam 4
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutoprazepam 4 mg
Study: 1974429
Drug: Flutoprazepam 2
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutoprazepam 2 mg
Study: 7323625
Drug: Tiapride (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (300 mg/day orally for 30 days)
Study: 31865235
Drug: Multiple Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Exposure treatment condition (at least 15 activities, exposed once)
Study: 31865235
Drug: Repeated Exposure
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated Exposure treatment condition (3 activities, exposed during five sessions each)
Study: 31865235
Drug: Multiple Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Exposure treatment condition
Study: 24337659
Drug: Propofol (2-3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2-3.5 μg/ml)
Study: 23174584
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose atorvastatin
Study: 19999921
Drug: Fast track
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast track group (epidural analgesia, early ambulation, oral feeding)
Study: 19999921
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no epidural analgesia, early ambulation, early oral diet)
Study: 16889491
Drug: T(4) treatment
Normalized name: 4-T-BUTYLCYCLOHEXANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: T(4) treatment in DS infants (N = 99)
Study: 16889491
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in DS infants (N = 97)
Study: 21111365
Drug: Tenecteplase (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (up to 2 mg) administered intraluminally, with a second dose if indicated and a third placebo dose.
Study: 21111365
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by up to two doses of tenecteplase if needed.
Study: 15675979
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids (500 ml intravenously during 4 h)
Study: 15675979
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution (500 ml intravenously during 4 h)
Study: 12166794
Drug: Triple dye
Normalized name: Triple Dye
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dye once followed by daily alcohol application
Study: 12166794
Drug: Daily alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily alcohol application alone
Study: 2281848
Drug: Midazolam (0.2-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.2-0.3 mg/kg b.w. i.v., group I n = 10)
Study: 2281848
Drug: Diazepam (0.3-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.3-0.4 mg/kg b.w., i.v., group II n = 10)
Study: 2281848
Drug: Flunitrazepam (0.03-0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.03-0.04 mg/kg b.w., i.v., group III n = 10)
Study: 23890856
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (total omega-3 6 g/d)
Study: 19246952
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral intake of 300 mg alpha‐tocopheryl‐acetate for 2 months
Study: 10753003
Drug: Sleep restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep restriction therapy combined with sleep hygiene
Study: 10753003
Drug: Nap modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nap modification of sleep restriction therapy combined with sleep hygiene
Study: 8631189
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (naringin, 887 mg/ml)
Study: 1420493
Drug: Phosphatidylcholine premixed
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine premixed dialysis solution
Study: 1420493
Drug: Control dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control dialysis solution
Study: 31451013
Drug: everolimus-eluting drug-eluting
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus-eluting drug-eluting stents (DES)
Study: 24585000
Drug: Postpartum oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postpartum oxytocin infusion of 80 U/500 mL over 1 hour
Study: 24585000
Drug: Postpartum oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postpartum oxytocin infusion of 80 U/500 mL over 8 hours
Study: 16375199
Drug: Inhaled short-acting
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled short-acting beta2 agonist
Study: 7951277
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (with side effects)
Study: 7951277
Drug: Treatment noncompliers
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment noncompliers
Study: 7951277
Drug: Hypothetical scenario
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical scenario with treatment compliance equal to placebo compliance
Study: 23510037
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg ranibizumab, treated as needed every 4 weeks (cohort A)
Study: 23510037
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg ranibizumab, treated as needed every 6 weeks (cohort B)
Study: 21279645
Drug: Wheat flour
Normalized name: Wheat Flour
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat flour inhalation
Study: 21279645
Drug: Rye flour
Normalized name: Rye
DrugBank: Rye (DB10564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rye flour inhalation
Study: 1593216
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg two times a day) with dimethyl sulfoxide (500 mg four times daily)
Study: 1593216
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg two times a day) with allopurinol (50 mg four times a day)
Study: 1593216
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg two times a day)
Study: 6095659
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg at bedtime)
Study: 1593216
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg two times a day) with dimethyl sulfoxide or allopurinol
Study: 29193877
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment for 10 days
Study: 25019115
Drug: Orabase treatment
Normalized name: ORABASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orabase treatment
Study: 23449351
Drug: FOLFOX/XELOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX/XELOX plus cediranib 20 mg (HORIZON II)
Study: 23449351
Drug: mFOLFOX6 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 plus cediranib 20 mg (HORIZON III)
Study: 19898259
Drug: Docetaxel/cisplatin/fluorouracil (TPF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/cisplatin/fluorouracil (TPF) combination chemotherapy
Study: 17045905
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g walnuts
Study: 17045905
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g olive oil
Study: 12781165
Drug: Exposure group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure group (daily tasting of the target vegetable for 14 days)
Study: 9863110
Drug: Xiaoliu Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoliu Tablet (XLT)
Study: 8306925
Drug: haloperidol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (40 mg a day) + carbamazepine (400 mg a day)
Study: 8306925
Drug: haloperidol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (40 mg a day) + bromocriptine (2.5 mg a day)
Study: 8306925
Drug: haloperidol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (40 mg a day) + cyproheptadine (24 mg a day)
Study: 8306925
Drug: haloperidol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (40 mg a day) + placebo
Study: 30146495
Drug: Aripiprazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (5 mg uncoated tablets)
Study: 30146495
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (300 mg uncoated tablets)
Study: 25190346
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (48 IU)
Study: 15941800
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (300 mg/d for 6 months)
Study: 8983316
Drug: Diclofenac resinate
Normalized name: cholestyramine resin / diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac resinate 75mg taken once or twice daily
Study: 8983316
Drug: Conventional enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional enteric‐coated diclofenac sodium 50mg tablets given two or three times daily
Study: 1931143
Drug: Active aspirin
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active aspirin and active beta-carotene
Study: 1931143
Drug: Active aspirin
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active aspirin and beta-carotene placebo
Study: 1931143
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin placebo and active beta-carotene
Study: 25801942
Drug: Ethanol (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (doses: 6, 12, 18, 24, 30, and 42 g)
Study: 21385352
Drug: Ward-based pharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ward-based pharmacy care from the clinical pharmacy team, including medication reconciliation at admission, daily medication review, and patient counselling at discharge.
Study: 21385352
Drug: Standard pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmaceutical care (Control group).
Study: 17405999
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg orally twice daily
Study: 10888712
Drug: leflunomide (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: leflunomide (loading dose 100 mg/day for 3 days, maintenance dose 20 mg/day)
Study: 10888712
Drug: methotrexate (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate (10-15 mg/week)
Study: 1526090
Drug: Ro 40‐5967
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 40‐5967 (150 mg)
Study: 1526090
Drug: Ro 40‐5967
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 40‐5967 (200 mg)
Study: 1526090
Drug: Ro 40‐5967
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 40‐5967 (50, 100, 150, 200 mg)
Study: 3549681
Drug: Imipramine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (3 mg/kg/day)
Study: 26227577
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (no feedback scales)
Study: 24030518
Drug: 10g gel-forming
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10g gel-forming pectin
Study: 23160228
Drug: SYSADOA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYSADOA group chemicals administered orally for 13 weeks
Study: 20560030
Drug: Intramyocardial BMMC
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial BMMC injection
Study: 18630763
Drug: I.M ketoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M ketoprofen (100 mg) + interpleural bupivacaine (0.4 ml/kg)
Study: 18630763
Drug: I.M pethidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M pethidine (1.5 mg/kg)
Study: 18630763
Drug: I.M ketoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M ketoprofen (100 mg)
Study: 18630763
Drug: interpleural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: interpleural bupivacaine (0.4 ml/kg)
Study: 11834852
Drug: Intralesional 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional 2.5 mg/ml verapamil hydrochloride injections administered at timed intervals
Study: 11834852
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the same treatment except the verapamil hydrochloride
Study: 11834852
Drug: Intralesional 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional 2.5 mg/ml verapamil hydrochloride injections
Study: 2680158
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg once daily)
Study: 2031046
Drug: Nebulized terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized terbutaline (5 mg inhaled 3 times daily) with PEP
Study: 2031046
Drug: Nebulized terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized terbutaline (5 mg inhaled 3 times daily) without PEP
Study: 30321947
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500mg twice a day
Study: 30321947
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice a day
Study: 28272250
Drug: Oxycodone IV-PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone IV-PCA (7.5 mg)
Study: 28272250
Drug: Fentanyl IV-PCA
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl IV-PCA (100 μg)
Study: 26433318
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control (review every 4 weeks, escalation of treatment if minimal disease activity criteria not met)
Study: 26433318
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (standard therapy according to the treating clinician, review every 12 weeks)
Study: 15084178
Drug: Daclizumab group
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab group (1 mg/kg daclizumab and 100 mg prednisolone for 3 days)
Study: 15084178
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (steroids tapered to 0 mg at week 16)
Study: 11165423
Drug: Low-Dose Oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Oral Alpha Interferon
Study: 9884853
Drug: Tropisetron (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (2 mg)
Study: 8004831
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil treatment for two years
Study: 28351782
Drug: FP/FOR (1000/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/FOR (1000/40 μg)
Study: 28351782
Drug: FP/FOR (500/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/FOR (500/20 μg)
Study: 28351782
Drug: FP/SAL (1000/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/SAL (1000/100 μg)
Study: 24228894
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day of extended-release isosorbide mononitrate added to standard therapy, titrated to 60 mg/day at week 6 if blood pressure exceeded 140/90 mmHg
Study: 24228894
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day of extended-release isosorbide mononitrate added to standard therapy
Study: 21129756
Drug: IVIG (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (2 g/kg)
Study: 19726593
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (150 microg I daily for 28 weeks)
Study: 17879366
Drug: Telaprevir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telaprevir (750 mg oral doses every 8 hours)
Study: 17879366
Drug: Telaprevir and
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir and peginterferon alfa-2a (telaprevir 750 mg every 8 hours and peginterferon alfa-2a 180 mug weekly subcutaneous injections)
Study: 16890357
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n=24) underwent conditioning with anaesthetic cream on one arm, followed by evaluation of pain intensity ratings.
Study: 16890357
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=16) did not receive the conditioning treatment.
Study: 10513866
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (MP) 125 mg intravenously